In a 36-year-old woman with seropositive rheumatoid arthritis, asthma, post-COVID ground-glass lung changes, who cannot tolerate methotrexate and sulfasalazine and plans future pregnancy, should anti‑TNF therapy be started now, and which anti‑TNF agent is preferred according to EULAR and ACR guidelines?

Anti-TNF Therapy is Appropriate Now, with Certolizumab as the Preferred Agent

Given your patient's intolerance to methotrexate and sulfasalazine, combined with her future pregnancy plans, initiating anti-TNF therapy now is strongly justified, with certolizumab pegol being the optimal choice due to its minimal placental transfer.

Rationale Based on ACR Guidelines

The 2020 ACR Guideline for Reproductive Health in Rheumatic and Musculoskeletal Diseases provides clear direction for your clinical scenario 1:

• Certolizumab receives a STRONG recommendation for continuation prior to and during pregnancy because it lacks an Fc chain, resulting in minimal placental transfer 1
• Other TNF inhibitors (infliximab, etanercept, adalimumab, golimumab) receive only conditional recommendations for use during pregnancy, as they contain IgG1 Fc constructs that cross the placenta significantly in the third trimester 1

Why Start Anti-TNF Now Rather Than Wait

Your patient has already failed two conventional synthetic DMARDs (csDMARDs) due to intolerance. According to both ACR and EULAR treatment algorithms:

• After csDMARD failure with poor prognostic factors (seropositive RA qualifies), biologic DMARD therapy should be added 2, 3
• The 2021 ACR RA Treatment Guideline emphasizes early escalation when initial therapy fails, with reassessment within 3 months 3
• Uncontrolled RA during pregnancy carries significant risks: increased miscarriage, preeclampsia, preterm birth, and low birth weight 4
• Maintaining disease control before conception is critical for favorable pregnancy outcomes 5, 4

Specific Agent Selection Algorithm

First choice: Certolizumab pegol

• Minimal placental transfer throughout pregnancy 1
• Can be continued through conception and entire pregnancy without modification 1
• Strong safety profile in reproductive-age women 5

Alternative options if certolizumab unavailable or ineffective:

• Other TNF inhibitors (adalimumab, etanercept) can be used during preconception and early pregnancy 1
• If disease well-controlled, these can be discontinued in third trimester (weeks 22-24 or later) 1
• However, if disease remains active, continuing through delivery may be necessary despite neonatal drug exposure 1

Addressing Her Specific Comorbidities

Post-COVID ground-glass lung changes:

• Anti-TNF therapy does not contraindicate use in patients with prior COVID-19 or residual pulmonary changes
• Monitor for infection risk, though TNF inhibitors have not shown increased COVID-19 severity in recent data 6

Asthma:

• TNF inhibitors are not contraindicated
• May actually improve systemic inflammation

Seropositive RA:

• This represents a poor prognostic factor, strengthening the indication for biologic therapy 2, 3

Critical Timing Considerations

Before pregnancy:

• Establish disease remission or low disease activity for at least 6 months before conception 3
• Certolizumab can be continued without interruption during conception attempts 1
• Methotrexate must remain discontinued (already done due to GI intolerance) - it is FDA Category X and contraindicated 7

During pregnancy:

• Continue certolizumab throughout all trimesters 1
• If using other TNF inhibitors, individualize third-trimester dosing based on disease activity 1

Monitoring Strategy

• Assess disease activity every 3 months initially 3
• Target remission or low disease activity before conception
• Coordinate care with maternal-fetal medicine once pregnant
• No routine live vaccines while on anti-TNF therapy 7

Common Pitfalls to Avoid

1. Do not delay biologic therapy waiting for pregnancy - uncontrolled RA worsens pregnancy outcomes more than medication exposure 4
2. Do not use JAK inhibitors (tofacitinib, baricitinib, upadacitinib) - no safety data in pregnancy and likely placental passage 1
3. Do not use rituximab as first-line - reserved for TNF-inadequate response or lymphoproliferative disease 3
4. Do not restart methotrexate - teratogenic and contraindicated in pregnancy planning 7

Documentation for Insurance Authorization

Cite the following to justify anti-TNF therapy:

• Failed two csDMARDs (methotrexate, sulfasalazine) due to intolerance
• Seropositive RA with poor prognostic features
• ACR 2021 RA Treatment Guideline recommendation for biologic therapy after csDMARD failure 3
• ACR 2020 Reproductive Health Guideline strong recommendation for certolizumab in pregnancy planning 1
• EULAR 2019 RA Management recommendations supporting biologic escalation with poor prognostic factors 2

Your approach is evidence-based, guideline-concordant, and prioritizes both disease control and reproductive safety.